PT Telekomunikasi Indonesia Tbk vs TransMedics Group Inc — how do they compare? PT Telekomunikasi Indonesia Tbk trades at $12.96 (market cap $12.43B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: PT Telekomunikasi Indonesia Tbk is far larger — about 4.5× TransMedics Group Inc's market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.48% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PT Telekomunikasi Indonesia Tbk for 0 Days and TransMedics Group Inc for 24 Days on average.
| TLK | TMDX | |
|---|---|---|
Market Cap | $12.43B | $2.74B |
Volume | 1,067,041 | 949,331 |
Sector | Media | Health |
52-Week High | $23.43 | $150.42 |
52-Week Low | $12.42 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $13.80B | $3.13B |
Dividend Yield | 9.48% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →